To help combat the COVID-19 pandemic, Lawrence Berkeley National Laboratory (Berkeley Lab) is offering special, time-limited, non-exclusive, royalty-free licenses to COVID-19-related intellectual property (IP) for which there are no conflicting obligations. These licenses are based on the AUTM COVID-10 licensing guidelines, which are also endorsed by more than 90 research institutions, including the University of California, Berkeley.
Berkeley Lab’s expectation is that licensees commit to rapidly make and broadly distribute licensed products and services to prevent, diagnose, treat, and contain COVID-19 or protect healthcare workers during the pandemic.
View the Lab’s available technologies on the Lab’s Intellectual Property Office website or the COVID-19 Innovation Portal on the DOE Lab Partnering Service website.
Contact [email protected] for more information. We welcome your interest and partnership in expediting solutions to this crisis.